BIO Stock Analysis: Buy, Sell, or Hold?
BIO - Bio-Rad Laboratories, Inc.Class A
$355.57
-22.14 (-5.86%)
▼
5d:
-8.25%
30d:
-6.66%
90d:
+19.78%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When BIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BIO trades at premium valuation expecting 6.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: BIO trades at premium valuation expecting 6.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$308.20
Based on 4.5% avg growth
INTRINSIC VALUE TODAY
$191.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIO is currently trading at $355.57, which is considered oversold relative to its 30-day fair value range of $372.45 to $387.72. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.9) compared to its historical average (30.0). At these levels, the market is pricing in 6.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIO is in a strong uptrend. The price is currently testing key support at $353.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: BIO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIO is in a strong uptrend. The price is currently testing key support at $353.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: BIO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$372.45 -
$387.72
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.0%
Protect Your Profits
Holding BIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.9%)
- BEARISH: Trading above Wall St target ($328.33)
- NEUTRAL: Trading at premium valuation - market expects 6.2% growth which is achievable
- CAUTION: 5-day price weakness (-8.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$372.45 -
$387.72
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$16.90
(4.8%)
Support & Resistance Levels
Support Level
$353.30
Resistance Level
$389.38
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.86
Wall Street Target
$328.33
(-7.7%)
Revenue Growth (YoY)
-0.1%
Earnings Growth (YoY)
18.7%
Profit Margin
8.6%
Valuation Premium vs History
+6.2% premium
PE vs Historical
35.9 vs 30.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.2%
(market-implied from PE analysis)
1-Year Target
$377.62
(+6%)
2-Year Target
$401.03
(+13%)
3-Year Target
$425.89
(+20%)
3-Yr Target (if PE normalizes)
(PE: 36→30)
PE COMPRESSION
$356.34
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.9, Growth: 4.9%)
$410.90
(+16%)
Base:
(SPY PE: 20.4, Growth: 4.9%)
$233.78
(-34%)
Bear:
(PE: 17.3, Growth: 4.9%)
$198.71
(-44%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (36x PE) as earnings recover.
Trailing PE: 46.29 | Current EPS (TTM): $8.20
Bull Case
$514.63
(+36%)
Analyst growth 23.3%, PE expands to 50.9
Base Case
$467.84
(+24%)
Market implied 23.3%, PE stable at 46.3
Bear Case
$258.09
(-32%)
Severe decline -20.0%, PE contracts to 39.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 01, 2026 5:02 PM ET
Data refreshes hourly during market hours. Next update: 6:02 PM
Data refreshes hourly during market hours. Next update: 6:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
Advanced BIO Option Strategies
Professional options setups generated by AI based on today's BIO price and gamma walls.
